Leukotriene E4

Leukotriene E4 (LTE4) 是肥大细胞和嗜酸性粒细胞等免疫细胞产生的半胱氨酰白三烯的稳定最终代谢产物,可作为评估哮喘严重程度、Aspirin (MS-D43752) 敏感性及肥大细胞活化障碍等关键生物标志物,也是 CysLT1R 的全功能激动剂,可诱导持续的细胞内钙动员和 Erk 磷酸化,并依赖 P2Y12 受体 (P2Y12 receptor) 介导炎症,可用于哮喘及非甾体抗炎药加重性呼吸系统疾病的研究。
产品编号: MS-V33626 纯度: 99.80% CAS No.: 75715-89-8 分子式: C23H37NO5S 分子量: 439.61
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
25μg (227.47μM * 250μL in Ethanol)
询价
3-5 天
50μg (227.47μM * 500μL in Ethanol)
询价
询价

产品描述

Leukotriene E4 (LTE4) 是肥大细胞和嗜酸性粒细胞等免疫细胞产生的半胱氨酰白三烯的稳定最终代谢产物,可作为评估哮喘严重程度、Aspirin (MS-D43752) 敏感性及肥大细胞活化障碍等关键生物标志物,也是 CysLT1R 的全功能激动剂,可诱导持续的细胞内钙动员和 Erk 磷酸化,并依赖 P2Y12 受体 (P2Y12 receptor) 介导炎症,可用于哮喘及非甾体抗炎药加重性呼吸系统疾病的研究。

生物实验数据

生物活性 Leukotriene E4 (LTE4) is the stable final metabolite of cysteinyl leukotrienes produced by immune cells such as mast cells and eosinophils, serves as a key biomarker for assessing asthma severity, Aspirin (MS-D43752) sensitivity, and mast cell activation disorders, acts as a full agonist of CysLT1R to induce sustained intracellular calcium mobilization and Erk phosphorylation, mediates inflammation in a P2Y12 receptor (P2Y12 receptor)-dependent manner, and can be used for research on asthma and nonsteroidal anti-inflammatory drug-exacerbated respiratory disease.
IC50 & Target

Human Endogenous Metabolite

 

CysLT1

 

P2Y14 Receptor

 

体外研究
(In Vitro)

Leukotriene E4 可在 LAD2 人肥大细胞中诱导浓度依赖性的持续性细胞内钙动员,其 EC50 为 1.67 nM。
Leukotriene E4 仅在 LUVA 人肥大细胞中诱导出非常微弱、非持续性的细胞内钙动员反应,且无法检测到 EC50。
Leukotriene E4 可在转染 CYSLTR1 的 HEK293T 细胞中诱导浓度依赖性的细胞内钙动员,其 EC50 为 83.2 nM。
Leukotriene E4 (100 nM; 2-60 min) 可在 LAD2 人肥大细胞中诱导 Erk 持续磷酸化,60 分钟后仍可检测到活化信号。
Leukotriene E4 (100 nM; 2-60 min) 可在 LUVA 人肥大细胞中诱导 Erk 发生短时程磷酸化,60 分钟内无持续激活。
Leukotriene E4 (1-100 nM; 15 min) 可在稳定表达人源 P2Y12 受体的中国仓鼠卵巢细胞中诱导 PTX 敏感、MK571 抗性的 ERK 磷酸化,其激活起始于 1 nM,在 100 nM 时达到平台期。
Leukotriene E4 (500 nM) 可诱导 LAD2 人肥大细胞发生钙内流,且该反应不受 P2Y12 拮抗剂 2-MesAMP (MS-W82349) 抑制。
Leukotriene E4 (100 nM) 可诱导人肥大细胞系 LAD2 产生 PGD2,且该产物的生成完全依赖于 P2Y12 受体。
Leukotriene E4 (1 μM; 10 min) 未诱导人血血小板中 CD62P 的表达 (活化标志物)。
Leukotriene E4 (100 nM; 2-6 h) 可通过 CysLT1 依赖机制诱导 LAD2 人肥大细胞中 CCL4 和 CSF2 mRNA 及蛋白的表达,其效力与 LTD4 相当或更强。
Leukotriene E4 (100 nM; 2-6 h) 在 LUVA 人肥大细胞中仅诱导极微弱的 CCL4 mRNA 和蛋白表达,其效力相对于 LTD4 极低。
Leukotriene E4 (100 nM; 2 h) 诱导人肥大细胞 LAD2 中 CCL4 mRNA 表达的过程依赖 MEK/Erk 通路以及细胞内/外 Ca2+,但不依赖 Gi/o 蛋白或 PPAR-γ 信号通路。
Leukotriene E4 (100 nM; 5 min-2 h) 需要长时间 (2 小时) 的作用才能在 LAD2 人肥大细胞中诱导完整的 CCL4 mRNA 表达,而短时间 (5 分钟) 的作用仅能引发微弱的活性。
白三烯 E4 (100-500 nM; 6 h) 可诱导 LAD2 人肥大细胞产生高水平的 MIP-1β,且该生成过程主要依赖 P2Y12 受体;P2Y12 拮抗剂 2-MesAMP 可抑制其生成的 50%以上,而 P2Y12 shRNA 敲低则可近乎完全阻断该生成过程。

Real Time qPCR

Cell Line: LAD2 human mast cells
Concentration: 100 nM
Incubation Time: 2 h (mRNA analysis); 6 h (protein analysis)
Result: Consistently induced CCL4 and CSF2 mRNA and protein expression, matching or exceeding the potency of LTD4.
Induced mRNA expression was fully inhibited by pre-treatment with 100 nM Montelukast (MS-X77797) for 10 minutes.
Induced mRNA expression was not affected by 1 μM HAMI3379 (MS-P80159).

Real Time qPCR

Cell Line: LUVA human mast cells
Concentration: 100 nM
Incubation Time: 2 h (mRNA analysis); 6 h (protein analysis)
Result: Induced only very weak CCL4 mRNA and protein expression.
Showed negligible activity compared to LTD4.

Western Blot Analysis

Cell Line: LAD2 human mast cells
Concentration: 100 nM
Incubation Time: 2, 5, 7, 10, 15, 30, 60 minutes
Result: Induced Erk phosphorylation that peaked later than LTD4-induced phosphorylation.
Induced Erk phosphorylation remained detectable for 60 minutes, showing sustained activation compared to the gradual decrease observed with LTD4.

Western Blot Analysis

Cell Line: LUVA human mast cells
Concentration: 100 nM
Incubation Time: 2, 5, 7, 10, 15, 30, 60 minutes
Result: Induced Erk phosphorylation that peaked at a similar time to LTD4-induced phosphorylation.
Induced Erk phosphorylation was shorter in duration than the sustained activation observed in LAD2 cells.

Real Time qPCR

Cell Line: LAD2 human mast cells
Concentration: 100 nM
Incubation Time: 2 h
Result: Induced CCL4 mRNA expression was potently inhibited by U0126, BAPTA-AM, and EDTA.
Induced CCL4 mRNA expression was not modified by pertussis toxin, GW9662, or T0070907.

Real Time qPCR

Cell Line: LAD2 human mast cells
Concentration: 100 nM
Incubation Time: 5 minutes, 2 hours
Result: 2-hour exposure induced CCL4 mRNA expression levels similar to those induced by LTD4.
5-minute exposure induced significantly lower CCL4 mRNA expression than 5-minute exposure to LTD4.

Real Time qPCR

Cell Line: CYSLTR1-knockdown LAD2 human mast cells
Concentration: 100 nM
Incubation Time: 2 h (mRNA analysis); 6 h (protein analysis)
Result: Induced CCL4 mRNA and protein expression was almost completely abrogated compared to empty vector control LAD2 cells.

Western Blot Analysis

Cell Line: Chinese hamster ovary (CHO) cells stably transfected with human P2Y12 receptor (forward orientation) or empty reverse construct control
Concentration: 500 nM (stimulation); 1 nM, 100 nM (dose-response analysis)
Incubation Time: 15 min (stimulation)
Result: Exhibited robust ERK phosphorylation in response to LTE4, with activation detectable at doses as low as 1 nM and reaching a plateau at 100 nM.
Showed partial block of LTE4-induced ERK activation by pretreatment with 2-MesAMP.
Showed LTE4-induced ERK activation sensitive to PTX and resistant to MK571.
Showed no ERK phosphorylation in response to LTE4 (reverse orientation P2Y12 construct cells).

ELISA Assay

Cell Line: LAD2 human mast cells
Concentration: 100 nM, 500 nM
Incubation Time: 6 h
Result: Induced substantial MIP-1β production at 100 nM and 500 nM, exceeding levels induced by LTD4 and IgE plus anti-IgE.
Blocked LTE4-mediated MIP-1β production by >50% after pretreatment with 2-MesAMP.
Nearly abrogated LTE4-induced MIP-1β production after P2Y12 receptor knockdown (reducing mRNA expression by ~90%).
Slightly (non-significantly) decreased the response to LTE4 after CysLT1R knockdown.
体内研究
(In Vivo)

Leukotriene E4 (2.2 nmol;滴鼻;每日 1 次;连续 3 天) 可显著增强致敏 BALB/c 小鼠中变应原诱导的肺嗜酸性粒细胞增多、支气管血管炎症及杯状细胞化生。
Leukotriene E4 (2.2 nmol;滴鼻;每日 1 次;连续 3 天) 可增强野生型 C57BL/6 小鼠中变应原诱导的肺部炎症,但该活性在缺失 P2Y12 受体的小鼠中被显著削弱。
Leukotriene E4 (2.2 nmol;鼻腔给药;每日 1 次;连续 3 天) 可在 BALB/c 小鼠中增强变应原诱导的肺部炎症,且该作用不依赖经典的 CysLT1R 和 CysLT2R 受体。
Leukotriene E4 (2.2 nmol;鼻腔给药;每日 1 次;连续 3 天) 介导的致敏 BALB/c 小鼠中变应原诱导的肺部炎症增强效应完全依赖于血小板。

Animal Model: BALB/c (male, 6-8 wk old, OVA (MS-Q48215)-sensitized asthma model)
Dosage: 2.2 nmol
Administration: i.n.; once daily; 3 days (30 minutes before each OVA challenge)
Result: Significantly enhanced bronchoalveolar lavage fluid eosinophilia.
Increased bronchovascular inflammation score per 15 bronchi to levels approaching those of mice challenged with 1% OVA.
Increased PAS-positive goblet cells per mm of bronchial basal lamina to levels approaching those of mice challenged with 1% OVA.
Modestly increased lung expression of IL-13 and MUC5AC mRNA.
Animal Model: C57BL/6 wild-type (male and female, 6-8 wk old, OVA-sensitized asthma model); C57BL/6 p2ry12-/- (age- and sex-matched, OVA-sensitized asthma model)
Dosage: 2.2 nmol
Administration: i.n.; once daily; 3 days (30 minutes before each OVA challenge)
Result: Potentiated bronchoalveolar lavage fluid eosinophilia, goblet cell metaplasia, and bronchovascular infiltration in wild-type mice.
Severely blunted all LTE4-mediated potentiation of these inflammatory endpoints in P2Y12 receptor-deficient mice.
Animal Model: BALB/c wild-type (6-8 wk old, OVA-sensitized asthma model); BALB/c Cysltr1/Cysltr2-/- (OVA-sensitized asthma model)
Dosage: 2.2 nmol
Administration: i.n.; once daily; 3 days (30 minutes before each OVA challenge)
Result: Potentiated OVA-induced bronchoalveolar lavage fluid eosinophilia, goblet cell metaplasia, and bronchovascular inflammation completely intact in CysLT1R and CysLT2R double-deficient mice, matching responses in wild-type controls.
Animal Model: BALB/c (male, 6-8 wk old, platelet-depleted, OVA-sensitized asthma model)
Dosage: 2.2 nmol
Administration: i.n.; once daily; 3 days (30 minutes before each OVA challenge)
Result: Completely eliminated LTE4-mediated potentiation of airway eosinophilia, bronchovascular inflammation, and goblet cell metaplasia, with effects identical to P2Y12 receptor blockade via clopidogrel.
Clinical Trial
NCT NumberSponsorConditionStart DatePhase
NCT01841164Karolinska University Hospital|Karolinska Institutet
Asthma
2012-05NA
性状 液体
颜色 Colorless to light yellow

化学信息

分子量 439.61
分子式 C23H37NO5S
CAS No. 75715-89-8
别名 LTE4

储存&溶解度

储存方式

Solution, -20°C, 2 years

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础